Within each therapeutic application, the market is further dissected by type, reflecting distinct pharmacological mechanisms and regulatory pathways. Antidepressants are sub‑typed into SSRIs, serotonin‑norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), and monoamine oxidase inhibitors (MAOIs); SSRIs alone capture roughly two‑thirds of the antidepressant sub‑market due to favorable safety profiles. Antipsychotics split into typical (e.g., haloperidol) and atypical (e.g., risperidone, olanzapine) agents, with atypicals representing about 70 % of sales driven by lower extrapyramidal side‑effect risk. Anxiolytics comprise benzodiazepines, non‑benzodiazepine hypnotics (Z‑drugs), and newer serotonin‑targeting compounds, each occupying roughly one‑third of the anxiolytic mix. Mood stabilizers include lithium salts, valproate, and lamotrigine, with lithium maintaining a legacy share despite competition. Stimulants are categorized as amphetamine‑based (e.g., dextroamphetamine) and methylphenidate‑based formulations, while sedatives/hypnotics are divided between classic barbiturates and modern orexin‑receptor antagonists. Pricing differentials among these sub‑types are amplified by patent expiries, generic entry timelines, and reimbursement policies, shaping competitive intensity across the portfolio. This type‑level taxonomy clarifies development pipelines and pricing dynamics across the psychotropic pharmaceuticals segmentation.
